Images from University of New Brunswick’s 195^th Encaenia Graduation Ceremony (May 2024)

Immunis, Inc., a private biotech creating innovative secretome therapeutics for age-related diseases and immune dysfunction, is thrilled to share that Chairman Dr. Hans Keirstead gave the Commencement Address to the 2024 graduating class from the University of New Brunswick (UNB) in Canada. Additionally, Dr. Keirstead was awarded with an honorary Ph.D. in recognition of his impactful academic and biomedical achievements in stem cell research.

Founded in 1785 as one of Canada’s oldest public universities, UNB is renowned for its contributions to innovation and entrepreneurship in the fields of engineering, computer science, and health sciences. The 2024 Fredericton Encaenia was filled with UNB graduates of science, nursing, and environmental management. Dr. Keirstead shared his incredible journey from Professor of Anatomy and Neurobiology to stem cell scientist to entrepreneur. This achievement serves as a personal honor for Dr. Keirstead, as both his father and grandfather studied at UNB.

In his powerful address, Dr. Keirstead shared that through his extensive career as a biomedical scientist, it was clear that “every pivot, every motivation, every inspiration comes as a result of an individual relationship with a person. People are everything.”

We congratulate the 2024 class of UNB graduates who are the future innovators of the world, and thank the university for recognizing Dr. Keirstead’s global achievements in human health.

About Immunis Inc.

Immunis is a private biotechnology company developing a novel immunomodulatory secretome product for the various manifestations of age and disease-related immune decline. The investigational product line leverages Immunis’ leading-edge capabilities in secretome technology to deliver a product of all natural, all human immune modulators in their natural relative physiological concentrations. For additional information about Immunis’ Phase 1/2a clinical trial please visit: https://immunisbiomedical.com/clinical-trials/

Cautionary Note Regarding Forward-Looking Statements

This communication contains statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as applicable. Forward-looking statements include, but are not limited to, statements regarding our plans, beliefs, expectations and assumptions, as well as other statements that are not necessarily historical facts. You are cautioned that these forward-looking statements are only predictions and involve risks and uncertainties. Further, any forward-looking statement speaks only as of the date as of which it is made, and we do not intend to update or revise any forward-looking statements. This communication also contains market data related to our business and industry which includes projections that are based on several assumptions we believe are reasonable and most significant to the projections as of the date of this communication. If any of our assumptions prove to be incorrect, our actual results may significantly differ from our projections based on these assumptions. This communication is neither an offer to sell nor a solicitation of an offer to buy any of the securities described herein.

Contact email: contact@immunisbiomedical.com